RayzeBio, Inc. announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the following investor conferences in November 2022: Jefferies London Healthcare Conference: Presentation on Wednesday, November 16 at 12:20 p.m. GMT in London, England.
- Jefferies London Healthcare Conference: Presentation on Wednesday, November 16 at 12:20 p.m. GMT (7:20 a.m. ET) in London, England.
- EvercoreISI HealthCONx Conference: Fireside chat on Wednesday, November 30 at 2:40 p.m. ET
RayzeBio will also be participating in 1x1 investor meetings at these conferences.
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005917/en/
Arvind Kush
info@rayzebio.com
Source: RayzeBio, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20221114005917/en
